Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) and XTL Biopharmaceuticals (NASDAQ:XTLB)

DBV Technologies (NASDAQ:DBVT) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares DBV Technologies and XTL Biopharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64 million	134.90	-$146.95 million	($3.51)	-3.45
XTL Biopharmaceuticals	$450,000.00	12.53	-$6.97 million	($0.64)	-3.72

XTL Biopharmaceuticals has lower revenue, but higher earnings than DBV Technologies. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

DBV Technologies has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for DBV Technologies and XTL Biopharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1	1	5	0	2.57
XTL Biopharmaceuticals	1	0	0	0	1.00

DBV Technologies presently has a consensus price target of $48.50, indicating a potential upside of 300.83%. Given DBV Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe DBV Technologies is more favorable than XTL Biopharmaceuticals.

Institutional & Insider Ownership

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares DBV Technologies and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
XTL Biopharmaceuticals	N/A	N/A	N/A

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.